For individuals on BP-lowering medication, we adjusted SBP by adding +15 mm Hg as per Evangelou et al.16,45. We used LDL-cholesterol from the UKB biomarker panel, measured at first UKB assessment. For individuals on lipid-lowering medication at the time of assessment (n = 66,737), we adjusted the measured LDL-cholesterol level by +1.5 mmol L−1.
